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In vitro maturation (IVM) and in vitro fertilization (IVF) technologies are facing with growing demands of older women
to conceive. Although ovarian stem cells (OSCs) of older women are capable of producing in vitro fresh oocyte-like cells
(OLCs), such cells cannot respond to IVM and IVF due to the lack of granulosa cells required for their maturation. Follicular
renewal is also dependent on support of circulating blood mononuclear cells. They induce intermediary stages of
meiosis (metaphase I chromosomal duplication and crossover, anaphase, telophase, and cytokinesis) in newly emerging
ovarian germ cells, as for the first time demonstrated here, induce formation of granulosa cells, and stimulate follicular
growth and development. A pretreatment of OSC culture with mononuclear cells collected from blood of a young
healthy fertile woman may cause differentiation of bipotential OSCs into both developing germ and granulosa cells. A
small blood volume replacement may enable treatment of ovarian infertility in vivo. The transferred mononuclear cells
may temporarily rejuvenate virtually all tissues, including improvement of the function of endocrine tissues. Formation
of new follicles and their development may be sufficient for IVM and IVF. The novel proposed in vitro approaches may
be used as a second possibility. Infertility of human males affects almost a half of the infertility cases worldwide. Small
blood volume replacement from young healthy fertile men may also be easy approach for the improvement of sperm
quality in older or other affected men. In addition, body rejuvenation by small blood volume replacement from young
healthy individuals of the same sex could represent a decline of in vitro methodology in favor of in vivo treatment
for human functional diseases. Here we propose for the first time that blood mononuclear cells are essential for
rejuvenation of those tissues, where immune system components participate in an appropriate division and
differentiation of tissue stem cells. If needed, small blood volume replacement from distinct young healthy individuals could
be utilized in six month intervals for repair of young altered or aged reproductive and other tissue functions. Systemic and
local use of honey bee propolis tincture is an alternative option for functional rejuvenation of some tissues.Editorial
The article series “IVF - the past, current development
and its future” [1] deals with IVF advances in research
over the past 10 years and its expected development
(reviewed in a blog by Natasha Salaria [2]). Of particular
interest are questions on how to improve IVF results in
older women and solve infertility in women with prema-
ture ovarian failure (POF) or other types of ovarian
infertility. In contrast to natural menopause, women di-
agnosed with POF may undergo unpredictable ovarian
function leading to intermittent and unpredictableCorrespondence: a_buko@comcast.net
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unless otherwise stated.menses in 50% of cases, and conceive and deliver a child
in ~5 to 10% of cases. In addition, other authors use the
term primary ovarian insufficiency (POI) [3] instead of
POF [4]. Most POF women, however, lack ovarian folli-
cles and there are no practical evidences that their infer-
tility can be solved by IVF, except for oocyte/embryo
donation cycles [5,6].
At present, it is obvious that the IVF approach is sub-
jected to the increased demands of older women. In de-
veloped world, “graying” of infertility populations and of
infertility services was recently reported by Norbert
Gleicher and colleagues as “an impeding revolution no-
body is ready for” [7]. In this IVF series article authors
reviewed this approach indicating that IVF live birthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical pregnancies between 46–53 years.
Heide Schatten and colleagues [8] deal with a vital role
of mitochondria in oocyte functions. Oocytes of women
affected by metabolic disorders, such as diabetes or
obesity and oocyte aging, can be improved by transfer of
mitochondria from cells with mitochondrial integrity
into mitochondria-impaired oocytes.
Deepa Bhartiya and colleagues [9] reviewed in vitro
approaches for the development of oocytes and sperm
from embryonic stem cells (ESC), induced pluripotent
stem cells (iPS cells), ovarian stem cells (OSCs), pluripo-
tent stem cells (PSCs), spermatogonial stem cells (SSCs),
and very small embryonic-like stem cells (VSELs). They
concluded that “Scientific community needs to slow
down, re-think and make efforts to exploit clinical po-
tential of pluripotent stem cells (VSELs) and progenitors
(SSCs and OSCs) which exist in the adult gonads as an
alternate option to ES/iPS cells.” They proposed: “Rather
than the existing concept of in vitro differentiation of stem
cells into oocytes and sperm for assisted reproduction, it
would be ideal to manipulate VSELs that survive
oncotherapy in vivo to achieve restoration of gonadal
function (since they exist in menopausal/POF ovary and
also in azoospermic human testis)” and “This approach
will give rise to autologous gametes, with no associated
ethical/regulatory constraints and epigenetic/genetic issues
may not exist by avoiding in vitro culture”.
Rationale for using in vitro developed oocyte-like cells
and possible IVM/IVF developments for clinical use
First report of in vitro differentiation of oocyte-like cells
(OLCs) from ovarian surface epithelium (OSE) cells of
adult human ovaries was published ten years ago [10].
To better understand a possibility of clinical use of
such in vitro developed OLCs for IVF purposes, or add-
itional possible IVM/IVF developments, one will need to
understand and review, including construction of this
article, how the germ and granulosa cells are developed
and processed in fetal mammalian ovaries and renewed
in later adult life, as well as conditions leading to atresia
of old primary follicles and formation of new primary
follicles for cyclic follicular renewal during the prime re-
productive period, but not thereafter.
In 1966 Erickson [11] reported that the numbers of
primary follicles in bovine ovaries remain stable until
7 years of age, and decline significantly thereafter, when
reproductive capacity begins to decline. Block [12] and
Gougeon et al. [13] showed that in women between 18-
38 ± 2.4 years of age, it is not possible to detect signifi-
cant changes in the number of oocytes and follicles.
If we take into account that at least 60% of oocytes in
adult human ovaries are in various stages of degener-
ation [14], we may conclude that without follicularrenewal the ovarian function will cease within a few
months. However, in aging ovaries, the elimination of
degenerating ovarian structures appears to be altered
along with a lack of regression of other temporary ovar-
ian structures (e.g. corpora lutea [15]), possibly due to
age-induced alterations of immune system functions, be-
ginning from the age of 35 years [16]. Due to the ab-
sence of corpora lutea during fetal immune adaptation
toward self tissues, they are considered to be a ‘graft’,
which results in their cyclical rejection during menstrual
cycles in adulthood [17]. The corpus luteum rescue dur-
ing pregnancy accompanies immune tolerance of fetal
allograft, and both effects required for successful preg-
nancy are considered to be caused by trophoblast-derived
chorionic gonadotropin and other endocrine factors
[18,19]. The cyclicity of ovarian function is considered to
be primarily dependent on the induction of a specific cyc-
lic immune response to the ovary [20]. In older females,
however, the regression of corpora lutea is affected, and
corpora lutea persist due to the developing senescence of
the immune system [15]. Due to the developing immune
senescence, atresia may not affect resting primary and
growing preantral follicles in aging ovaries [13], and such
follicles may persist in spite of accumulation of environ-
mental and genetic alterations of oocytes in older women.
It is important to indicate that older fathers may con-
tribute just as much as older mothers to the dramatic in-
crease in Down syndrome risk in older couples. A recent
study found that fathers older than 40 years of age were
responsible for up to 50% of the rise in Down syndrome
risk when the mother was also over 40 [21]. Of note, the
number of births in couples over 35 years of age has
more than doubled in the last 20 years and this has
raised questions about the role of paternal age in the risk
of genetic abnormalities and birth defects [21].
Formal terms related to the ovarian cellular conditions
and functions
In this article, the following formal terms are used:
Ovarian Stem Cells (OSCs) for the bipotential stem
cells causing granulosa and germ cells origin; ovarian
Fetal germ cells and Adult germ cells - (see Ref. [22]
for testicular fetal and adult germ cells) instead of non-
existing persisting primordial germ cells, germline stem
cells, or oogonial stem cells. New primary follicles (see
Ref. [23]) instead of non-existing primordial ovarian folli-
cles; Resting primary follicles instead of non-existing
resting primordial follicles; Growing preantral follicles;
Small antral follicles (suitable for IVM); and Large
antral follicles (suitable for IVF).
Ovarian VSELs are, in reality, cytokeratin (CK) and
major histocompatibility complex class I (MHC-I) posi-
tive OSE cells [24], later called ovarian stem cells [10],
each measuring about 4 microns in diameter. They lose
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fetal germ cells or adult germ cells, but not when trans-
formed into granulosa cells [24,25].
Ovarian stem cells regenerate from their CK positive
fibroblast type cell precursors present after the birth in
the developed tunica albuginea (TA) (see Figure two in
Ref. [23] and below). Genetically, CK and MHC-I posi-
tive OSCs are precursors of CK and MHC-I positive
granulosa cells. The role of embryonic primordial germ
cells is to commit OSCs for production of fetal and adult
germ cells (see Figure five in Ref. [26]).
Stem cell commitment by embryonic primordial germ
cells
The commitment by primordial germ cells gives OSCs a
possibility to differentiate into distinct cell types, includ-
ing neural/neuronal cells [27]. Certain pluripotency of
stem cells in some other tissues may also be established
by primordial germ cell settlement during the embryonic
period, since they circulate in embryonic blood vessels
[28]. It has been reported that those OLCs expressing
oocyte markers, such as Oct4, Vasa, Bmp15, and Scp3,
may even be developed from porcine skin stem cells
[29]. However, this line of research has been abandoned
since OLCs remain unable to undergo maturation or
fertilization because they do not complete meiosis [30].
Roles of the immune system in ovarian function
Since the late 1970s, we have been involved in analyzing
the role of the immune system in the regulation of nor-
mal ovarian function [20]. In 1995 we showed for the
first time that during the reproductive life of women,
OSE cells form in vivo new granulosa cell nests and,
with the assistance of immune system cells, they are a
source of new adult germ cells for follicular renewal
[24]. Therefore, the OSE cells represent in vivo bipoten-
tial OSCs.
Steps required for follicular renewal in adult human ovaries
To deal with the treatment of ovarian infertility, the re-
searches and physicians should be aware of the following
issues occurring in adult (and fetal) ovaries which are
listed below. During follicular renewal in adult human
ovaries, the following conditions were observed and
interpreted: [10,17,23-27,31-35] (see also Figures below):
1. Availability of adult germ cells passing meiosis I
metaphase with chromosomal crossover.
2. Availability of adult germ cells differentiated into the
meiosis I telophase and cytokinesis stage.
3. Their migration guided by the CD14 and DR+ MDCs,
and entering into blood venules in the upper ovarian
cortex for vascular transport to the lower ovarian
cortex (about 1000 microns distance).4. Differentiation and association of granulosa cell nests
with cortical venules in the lower ovarian cortex
5. Assembly of circulating oocytes with granulosa cell
nests to form new primary follicles.
6. Formation of the oocyte’s primary and secondary
Balbiani bodies (see below) from granulosa cells,
which supply new specific organelles needed for
early oocyte development and advanced oocyte
growth with meiosis II resumption.
Absence of any of these steps, some of which require
proper functioning of the ovary-committed immune sys-
tem components and vegetative innervation, may result
in functional infertility, which would be difficult, if not
impossible, to treat by currently available IVM and IVF
approaches.
Origin and development of ovarian germ cells
Figure 1 demonstrates that adult germ cells do not ori-
ginate from persisting oogonia (so called primordial
germ cells or oogonial stem cells) but from cytokeratin
positive OSCs. Origin of adult germ cell is initiated by
an association of a primitive CD14+ monocyte derived
cell (MDC) causing OSC division, and by CD8+ T cell
causing that one of resulting daughters begins to develop
in a distinct way, via asymmetric division [36]. The CD8
T cell is also expressing HLA DR (see below) causing its
activation. It invades the developing adult germ cell and
causes expression of PS1 meiotically expressed carbohy-
drate protein [37] accompanying chromosomal duplica-
tion and crossover during meiosis I prophase and
metaphase (see below).
The CD14+ MDC binds to developed adult germ cell,
causes meiosis I cytokinesis, and divides in the TA. Next,
the primitive CD14 cells become activated (HLA DR+)
and transport adult germ cells from the TA to blood ve-
nules in the upper ovarian cortex. In other words, those
MDCs coming to the ovary from TA venules participate
on asymmetric origin of germ cells from OSCs, cause
symmetric meiosis I division of germ cells, and forward
the germ cells toward the cortical venules, back from where
the MDCs entered the ovarian upper cortex and the TA.
Figure 2 shows that primordial germ cells do not per-
sist even in fetal ovaries, but new germ cells originate
from CK+ OSCs with the assistance of immune cells.
Multi-layered fetal OSC epithelium exhibits an emer-
gence of numerous fetal germ cells with a depletion of
MHC-I expression. After asymmetric division with cross-
over of chromosomes, a symmetric meiosis I division of
germ cells soon follows and mowing germ cells leave the
OSC epithelium toward granulosa cells in the adjacent
ovarian cortex to form fetal primary follicles (see Ref.
[25,34] for details). Note the absence of the TA, containing
OSC and granulosa cell precursors, which is formed in
Figure 1 Immune type cells influence commitment of OSCs in adult human ovary (age 32 years, midfollicular phase). A) Primitive CD14
MDC (green asterisk) associates with a small OSC (yellow asterisk and dotted circle) accompanying origination (green arrowhead) of a larger germ cell (red
asterisk and dashed line) by asymmetric division of OSC (red arrowhead). B) A serial section shows that asymmetric division is also accompanied by CD8
T cell (white asterisk) entering germ cell and exhibiting extensions (white arrowhead). C) Divided primitive CD14 MDC (green asterisks) accompany (green
arrowheads) symmetric division (meiosis I cytokinesis) of germ cells (red asterisks) in the TA (ta) and germ cells moving (arrow) into the adjacent upper
ovarian cortex (uoc). Inset shows a blood venule in the upper ovarian cortex with Thy-1 differentiation protein expression by vascular pericytes (arrow)
and venule lumen (vl) containing a germ cell (red asterisk). D) Germ cell transport in the upper ovarian cortex is associated with an attached activated
(DR+) MDC (green asterisk and dotted lines) releasing DR+ cytoplasmic particles (green arrows) which accumulate at the surface of the germ cell nucleus
(arrowhead). E) Endothelial cells (en and open arrows) of a venule in the upper ovarian cortex exhibit MHC-I expression, which is not
expressed by associated migrating (red arrow) germ cell (asterisk). See text for additional details. Adapted from Ref. [24], with a permission: © Blackwell
Publishing, Oxford, UK.
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available in Ref. [23]), see also below.
Like in adult ovaries, the emergence of germ cells by
asymmetric division is accompanied by CD8 T cells ex-
pressing HLA DR. That was also observed in T cells
undergoing suicide during differentiation of epithelial
cells [36].
Beside origin of germ cells, OSCs also are a source of
primitive granulosa cells that emerge between ovarian
mesenchymal cell cords and contribute granulosa cells
to the formation of fetal primary follicles (see Ref.
[25,34] for details). Activated (DR+) MDCs accompany
growing fetal follicles, but not resting ones. Thy-1+ vas-
cular pericytes also associated with growing but not with
resting follicles, like in adult ovaries [24].
Figure 3 demonstrates that PS1 meiotically expressed
carbohydrate protein [37] is expressed by ovarian adultgerm cells and small oocytes, and association of zona
pellucida (ZP) expressing oocyte with CK+ granulosa
cell nest during follicular renewal in a 28 year old
women. Dual color immunohistochemistry (IHC) shows
asymmetric division of OSC during mitotic anaphase.
The dividing cell consists of a small blue CK+ OSC and
PS1+ brown large germ cell. The OSC chromatids are
moving during mitotic anaphase to the OSC daughter
end. A putative CD8/DR+ suicidal T cell (see Figures 1B,
2D,E, and Ref. [36]) is expressing PS1 and induces PS1
expression in its surroundings (red arrowheads, Figure 3A).
In reality, the presence of CD8/DR+ T cell within emerging
germ cell causes that the developing germ cell is already
in the meiosis I metaphase, when the chromosomes du-
plicate and homologous chromosomes exchange genetic
information (chromosomal crossover) before meiosis I
anaphase. Inset in Figure 3B shows a detail of the
Figure 2 Formation of fetal germ cells, granulosa cells, and follicular development in midpregnancy human fetal ovary. A) CD14 MDC
interacts (arrowheads) with an OSC (yellow asterisk and dotted circle) prior to the asymmetric division. B) Numerous MHC-I depleted fetal germ
cells (blue asterisks and dashed circles) originating by asymmetric divisions (arrowhead) from MHC-I+ OSCs (yellow asterisks and dotted circles).
C) Asymmetric division (blue arrowhead) is followed by a symmetric division of MHC I depleted germ cells (red asterisks and arrowhead). This is
followed by the development of ameboid shape fetal moving germ cell (mgc - dashed line, no hematoxylin counterstain) entering adjacent
ovarian cortex. Asymmetric division is accompanied by CD8 (D) and DR+ (E) T cell. F) CD14 MDC (arrowhead) accompanies symmetric division
of germ cell during meiosis I telophase. G) Development of primitive granulosa cells (pgrc, note lower CK expression) from ovarian stem cells
between mesenchymal cell cords (mcc). H) DR+ MDC accompany (arrows) fetal growing follicle (gf) but not the resting follicle (rf). Inset shows
association of Thy-1+ pericytes (arrowhead) with a growing but not resting follicles. Bar in A for A-F. Adapted from Ref. [25] with a permission:
© Springer US.
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mata of sister chromatids during meiosis I metaphase
(see Ref. [38] for review).
Strong nuclear PS1 expression was detected in adult
germ cells in meiosis I telephase indicating involvement of
PS1meiotically expressed carbohydrate protein in meiosis
I events. Germ cells migrating from the TA to the upper
ovarian cortex exhibit a diminution of nuclear PS1 expres-
sion. Germ cells in the upper ovarian cortex resemble
small oocytes and exhibit strong cytoplasmic PS1 expres-
sion only. They enter the adjacent cortical veins.
The vascular transport of small oocytes in adult hu-
man ovaries is usually required for later association with
granulosa cell nests in the lower ovarian cortex (about
1000 microns from the ovarian surface). In contrast, hu-
man fetal ovaries are much smaller and do not requirevascular transport, since oocytes attain developed granu-
losa cells by their own movement [25]. The same applies
for adult small laboratory rodents, like rats [39]. Figure 3
also shows follicular renewal with blue zona pellucida
staining of a small oocyte and brown staining of CK+
granulosa cell nest in the lower ovarian cortex of the
same 28 year-old woman.
Some exemptions may, however, occur on adult hu-
man ovaries. When the OSC epithelial crypts reach by
invagination the lower ovarian cortex, they produce
germ cells able to move by their own movement (with-
out vascular transport) to the neighboring granulosa cell
nests to form new primary follicles. The granulosa nests
reach the lower ovarian cortex within stromal sprouts
migrating from the upper cortex under the influence of
DR+ MDC (see Figure twelve in Ref. [23]).
Figure 3 Origin, meiosis I, and migration of human adult germ cells, and follicular renewal in a 28 year old women (F28). A) Dual color
IHC of asymmetrically dividing OSC with CK+ (blue dashed line) OSC daughter and PS1+ (red dashed line) germ cell daughter. CK+ OSC daughter
chromosomes (white arrowhead) move to the OSC end during mitotic OSC anaphase. Germ cell chromosomes (white arrows) duplicate by DNA
replication (red and blue arrows) and exhibit metaphase I sister chromatid crossover (orange arrows) during meiosis I metaphase. White asterisk and
dotted circle indicate PS1+ putative CD8/DR+ suicidal T cell within the germ cell (see Figures 1B, 2D,E and Ref. [36]). B) In the TA (ta) the symmetrically
dividing germ cell exhibits strong nuclear (asterisks) PS1 expression, which accompanies the meiosis I telophase. Arrow indicates a germ cell moving
from the TA to the upper ovarian cortex (uoc). Inset shows a detail of chromosomal crossover (orange arrows) from panel A. Red and blue arrows
indicate interacting sister chromatids. C) Germ cell with a diminution of nuclear and increase of cytoplasmic PS1 staining. It begins to enter (arrowheads)
the vein in the upper ovarian cortex. D) Early stage of new primary follicle formation with ZP (blue color) expression of a small oocyte captured by the
CK+ (brown color) granulosa cell nest. See details in the text. Adapted from Ref. [3]: © Antonin Bukovsky.
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with primary Balbiani body formation in the identical
ovary of a 28 year old woman, and the fate of circulatingoocytes lacking association with granulosa cells. Granu-
losa cell nests for follicular renewal are formed during
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Figure 4 Follicular renewal in adult human ovary and intravascular degeneration of germ cells unattended with granulosa cells. A)
Ovarian vein in the lower ovarian cortex lined by endothelial cells (en) and CK+ granulosa nest wall (gnw). In the vein lumen (vl) the granulosa
nest wall extends a granulosa nest arm (gna) capturing the circulating oocyte (co). B) Granulosa nest (gn) during formation of the new primary
follicle with captured oocyte. Granulosa cells penetrate the ooplasm (red arrowheads) during the primary Balbiani body (asterisk) formation
adjacent to the oocyte nucleus (on). CK+ granulosa nest particles (yellow arrowheads) are already dispersed within the oocyte, which still exhibits
oocyte tail (ot) outside of the new primary follicle. C) Growing follicle (dashed line circle), with granulosa cells (grc) and oocyte (o) with ZP
expression at the oocyte surface (arrow). D) Degenerating oocyte in a medullary vein from the same ovary as in panel C exhibits a strong
cytoplasmic ZP expression. E) Heavily ZP+ degenerating oocyte from 28 year-old fertile woman found in the extra ovarian (uterine ectocervix)
vein of a patient with follicular renewal shown in panels 4A and 4B. Panels A and B adapted from Ref. [23] : © Antonin Bukovsky; panels C-E
adapted from Ref. [41] , with a permission: © Elsevier/North-Holland Biomedical Press.
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reach venules in the lower ovarian cortex, CK+ granu-
losa nest walls replace vein’s endothelial cells and the
granulosa nest arm captures a circulating oocyte from
the vascular lumen (Figure 4A).
Figure 4B demonstrates that the CK+ oocyte’s pri-
mary Balbiani body adjacent to the oocyte nucleus is
already formed by granulosa cell nest extensionspenetrating into the ooplasm very early during follicular
renewal, at the time when the oocyte tail is still outside
of the developing new primary follicle. Cytokeratin posi-
tive particles within the ooplasm suggest a fast release of
the Balbiani body components. It contains additional
organelles, such as Golgi vesicles, endoplasmic reticulum
membranes, and nascent forms of smooth endoplasmic
reticulum, needed by oocytes to develop further [40].
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nest assembly and primary Balbiani body formation see
Figures five to eight in Ref. [23].
Before and after reaching the new primary follicle
stage, oocytes show ZP expression at the oocyte surface
[41]. Oocyte surface ZP expression in a growing pre-
antral ovarian follicle of a 34-year old woman is pre-
sented in Figure 4C. In the same women, the medullary
vessels show degenerating oocytes with heavy cytoplasmic
ZP expression (Figure 4D).
During follicular renewal, ZP+ degenerating oocytes
were even detected in the vessels outside of the ovary
(Figure 4E) of the same 28 year old woman with follicu-
lar renewal shown here. This indicates that, during
human follicular renewal, oocytes circulate through the
blood stream, and those which are unable to associate
with available ovarian granulosa cell nests degenerate.
Thus during follicular renewal, the number of newly
formed adult germ cells is significantly higher than the
number of newly formed granulosa cell nests [23]. In other
words, the number of developed granulosa cell nests in a
given ovarian cycle determines how many new follicles will
be formed. Consequently, if no granulosa cell nest are
formed, no follicular renewal occurs (e.g., after 38 ± 2 years
of age). Even if adult germ cells are still available in aging
mammals [42], the lack of uncommitted granulosa cell
nests causes a lack of formation of new primary follicles.
Functional tissue longevity depends on the timing of
their appearance during early periods of life - the tissues
appearing very early during immune adaptation, like the
hart, can in humans function for one hundred years
[43]. The presence of germ cells in aging mammals is
caused by their early appearance - during embryonic adap-
tive period of development, while lack of granulosa cells in
aging mammals is caused by their later appearance - dur-
ing the fetal adaptive period of development [34].
Figure 5 demonstrates formation of fresh OSCs differ-
entiating from the TA CK+ fibroblast-like precursors and
cyclic emergence of OSC-derived granulosa cell nests for
follicular renewal. CK+ fibroblasts in the TA (OSC pre-
cursors formed perinatally from fetal OSCs) and their
early transformation into adults OSCs under the ovarian
surface are presented. When the epithelial type OSCs are
formed, the CK staining in their precursors diminishes.
To form granulosa cells, the OSCs at the ovarian surface
are overgrown by the TA flap. A completed OSC channel
collapses into a bilaminar OSC cord. The OSC formation
from CK+ precursors is accompanied by numerous DR+
MDC, and developing OSCs are DR+. Bilaminar OSC
cord lying on upper ovarian cortex is covered by the TA.
The process of granulosa cells formation with TA flap
and new OSCs at the ovarian surface pretends the frag-
mentation of granulosa cell clusters into granulosa cell
nests, occurring at about 300 microns down from thesurface. The granulosa cell nests move by stromal rear-
rangements to the lower ovarian cortex. At a distance of
about 1000 microns from ovarian surface, the follicular
renewal is apparent. As expected, the new primary folli-
cles exhibit CK+ primary Balbiani bodies. Resting pri-
mary follicles occur at the same distance from ovarian
surface, but, unexpectedly, show no Balbiani bodies,
possibly due to their complete utilization by the resting
primary follicles, which may be required for the further
oocyte growth in preantral follicles.
Taking together, the Figure 5 shows four simultaneous
processes, which may have a sequential cyclic origin,
each of which should be accompanied by a formation of
new adult germ cells. The first two of cyclic formations
may not succeed to form the new primary follicles. They
include development of new OSCs in the first ovarian
cycle, formation of granulosa cell nests in the upper
ovarian cortex during the second cycle, movement of
granulosa cell nests to the lower ovarian cortex and for-
mation of new primary follicles during the third cycle,
and development of resting primary follicles, part of
which will be destined for the growth of preantral folli-
cles, during the fourth cycle. The development of small
antral follicles, suitable for IVM, since they exhibit a sec-
ondary Balbiani body formation derived from granulosa
cells (see below), can be expected during the fifth cycle,
and development of large antral follicles, suitable for
IVF, can follow during the sixth cycle. In other words,
the effective outcome of in vivo treatment after a small
blood volume replacement or mononuclear cells transfu-
sion suggested below can be expected after 4-6 ovarian
(menstrual) cycles, i.e., 4-6 months, depending on the
choosing the IVM or IVF approach.
Ovarian stem cell cultures
Oocyte like cells developed in OSC cultures are very im-
mature, since they do not exhibit ZP3 expression and CK
positive Balbiani bodies. Observations from time lapse
photography [34] (Figure 6) have shown that early devel-
oping oocytes have few optically dense cytoplasmic organ-
elles. They appear to be smart and join fibroblast-type cells
which provide additional organelles. Such fibroblast-type
cells initially show optically dense organelles close to the
nucleus, but not in the arm extended toward the oocyte.
Within 10 min from the previous photograph, however,
optically dense organelles are evidenced in the extended
fibroblast arm, within adjacent oocyte cytoplasm, and also
in distant oocyte regions. After 4 h and 25 min, however,
the fibro-oocyte hybrid is formed and the dominant
fibroblast cell collects organelles from regressing oocyte.
The smarter OLCs produce a satellite daughter cell
and are supplied of additional organelles with an ex-
tended tube. When supply is completed after 1 h and
39 min, the tube disappears and the satellite is
Figure 5 Cyclic formation of OSC, granulosa cells nests, and presence of new and resting primary follicles during midfollicular phase.
A) Tunica albuginea (ta) fibroblasts (fb) type OSC precursors with CK immunoexpression (brown). Two cells in mesenchymal-OSCs epithelial transition
(fb/osc) are apparent. B) Appearance of OSCs (osc) is associated with CK depletion (-fb). C) Formation of CK+ granulosa cell nests is initiated by a layer
of OSC (white arrows) above upper ovarian cortex (uoc). This is overgrown by a developing flap of TA (ta flap or taf in insert) resulting in a bi-layered
osc cord (black arrow). Inset shows two layers of the OSC channel. D) Detail of OSC flap with CK+ fibroblast type OSC precursors (fb/osc), and OSC
development above the upper ovarian cortex (arched arrow). Arrowhead indicates the flap content of OSCs. E) A parallel section to (D) showing
numerous DR+ MDC (asterisks) in the TA flap. Note DR expression in early OSC (arrow). F) Detail of OSC-cord from panel C shows CK+ epithelial cord.
G) OSC flap (red arrowhead) over a segment of TA (dashed line) covered by OSC layer (red arrow). The OSC cord-derived granulosa cell clusters (black
arrows) fragment into granulosa cell nests (black arrowheads). Dashed line indicates a segment of TA covered by OSC epithelium. H) Granulosa cell
nests (black arrowheads) move by stromal rearrangements (arched arrow) to the lower ovarian cortex (loc) and form new primary follicles (white
arrowhead) containing ZP+ oocytes. I) Lower ovarian cortex (loc) with new primary (right panel segment) and resting primary follicles (left). Right inset
shows the presence of primary Balbiani bodies. Left inset shows lack of Balbiani bodies. Bar in (A), for (A and B), bar in (F) for (D-F). Adapted from Ref.
[23]: © Antonin Bukovsky.
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Figure 6 In vitro developing oocytes are supplied with meiotically nonfunctional organelles from fibroblasts or satellite cells. Time
lapse photography shows that early developing oocytes (o, panel A) are low in optically dense cytoplasmic organelles (white open arrow). They
can be joined (arrowhead) by fibroblast-like cells (fb), providing additional organelles. Such fibroblast-type cells initially show optically dense organelles
close to the nucleus (black solid arrow), but not in the arm extended toward the oocyte (white solid arrow). Within 10 min (panel B), however, the
optically dense organelles are apparent in the extended arm (solid black arrow) and within adjacent oocyte cytoplasm (black arrowhead) and
distant oocyte regions (black open arrow). At 4h 25 min (panel C), however, the fibro-oocyte (fbo) hybrid is formed and regressing oocyte (ro)
exhibits depletion of organelles (arrow) accumulated by the fibroblast (arrowhead). Alternatively, the developing oocytes (o, panel D) deficient
in cytoplasmic organelles (white arrow) exploit the satellite cells (s), which are produced by the oocytes themselves. The oocyte is supplied by
suicidal satellite cell by a tube like ring canal - (black arrowhead; see inset). In panel E the oocyte exhibits enhanced content of the optically
dense organelles (black arrow) and the ring canal draining the satellite disappears (white arrowhead - see inset). The satellite cell size is reduced
(dashed line) and the perinuclear space is altered (compare with panel D). Oocytes enriched by satellites’ organelles (panel F) exhibit good morphology
[200 micron size, germinal vesicle (gv), and thick zona pellucida (zp)], but are unable to resume meiosis II due to the lack of meiotically functional
organelles provided by secondary Balbiani body derived from granulosa cells in vivo. Bar in A for A-E. Panel C reprinted from Ref. [26]: © Antonin
Bukovsky. Other panels adapted from Ref. [34], with a permission: © Wiley-Liss, Inc.
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OLCs with a germinal vesicle (GV), thick ZP, and flat
OLCs of 200 microns in diameter, the lack of secondary
Balbiani body with granulosa cell organelles enabling the
oocyte to respond gonadotropins may be a cause of a
failure for meiosis II resumption.
Perspectives of advanced woman age, premature ovarian
failure, or other ovarian infertility etiologies by in vitro
developed oocytes in ovarian stem cell cultures
The advantage of in vitro OLCs development from cul-
tured OSCs is that it is age-independent and does not
require the presence of any germ and granulosa cells or
ovarian follicles in the ovaries.
Ovarian stem cell cultures do not consist of OSCs
alone. They contain also other cell types accompanying
OSCs and adjacent TA, since the cellular content is
scrapped from the ovarian surface as indicated previ-
ously [10]. The following cell types detected immunohis-
tochemically [10,23-25] may, or may not be present:
OSC-CK+ fibroblast-like precursors, OSCs, germ cells
from asymmetric division of OSCs, germ cells in
chromosomal crossover, germ cells in meiosis I division,
post-meiosis I migrating germ cells, fibroblasts, Thy-1+
vascular pericytes, CD14 and DR+ MDCs, CD8 and DR
+ T cells, endothelial cells, and possibly other cell types.
Unfortunately, the former clinical trial in 2006, accom-
panied by IVM, was unsuccessful due to the absence of
properly differentiated OLCs which attract spermatozoa
to be fertilized - reported in Ref. [26], although a single
preblastocyst like structure was found after in vitro insem-
ination [44]. Nevertheless, in vitro cultured OSCs are cap-
able of forming parthenogenetic embryos [26], which may
be a source of autologous stem cells, and also autologous
neural and neuronal cells after sex-steroid treatment [27].
Nuclear transfer
To prevent mitochondrial disorders, it has been demon-
strated in non-human primates that the mitochondrial
genome can be efficiently replaced by spindle-chromo-
somal complex transfer from one oocyte to an enucle-
ated, mitochondrial-replete egg. The reconstructed
oocytes with mitochondrial replacement were capable of
supporting normal fertilization, embryo development,
and produced healthy offspring [45]. More recently, this
group studied the feasibility of mtDNA replacement in
human oocytes by spindle transfer (ST). Fertilization rate
in ST oocytes (73%) was similar to controls (75%). How-
ever, a significant portion of ST zygotes (52%) displayed
abnormal fertilization as determined by irregular num-
ber of pronuclei. Among normally fertilized ST zygotes,
blastocyst development (62%) and ESC isolation (38%)
rates were comparable to controls [46]. Recent commen-
tary of John Zhang [47] recommended a revision of GVtransfer for the treatment of infertile women with dimin-
ished ovarian reserve.
Similar experiments to prevent the transmission of
human mitochondrial mutations by mitochondrial gene
replacement were performed by another group [48]. The
authors reported that defective mitochondrial DNA
accidentally transferred with the nuclear genome was ini-
tially detected at levels below 1%, decreasing in blastocysts
and stem-cell lines to undetectable levels, and remaining
undetectable after passaging for more than one year, clonal
expansion, differentiation into neurons, cardiomyocytes or
ß-cells, and after cellular reprogramming. Stem cells and
differentiated cells had mitochondrial respiratory chain
enzyme activities and oxygen consumption rates indistin-
guishable from controls. These results demonstrated the
potential of nuclear genome transfer to prevent the trans-
mission of mitochondrial disorders in humans.
Novel in vitro proposals for ovarian infertility treatment
Preliminary strategies for in vitro approaches
Ovarian stem cells carry imprint from primordial germ
cells to develop into distinct cell types including human
OLCs [10] or neural stem cells [27]. Such a differentiations
just depend on culture medium conditions, and sex steroid
components in particular. Development of OLCs was also
observed in porcine skin stem cells [29]. The stem cells
used for generation of OLCs may have an imprint from
primordial germ cells to behave like oocytes, e.g., to in-
crease the content of cytoplasmic organelles by fusion with
other cell types present, or from their own daughter cells
(see Figure 6). However, they may not exhibit meiosis-I
chromosomal crossover mediated by OSC committed
CD8/DR+ T cells, meiosis I symmetric division (cytokin-
esis) mediated by OSC-committed CD14 MDC. Due to
the lack of granulosa cells the primary and secondary
Balbiani bodies, which are necessary for an early oocyte
development and later meiosis II resumption, are absent.
Formation of germ cells
For the testing of in vitro approaches, OSCs are collected
from oophorectomy samples, regardless of the patient’s
age [10]. To avoid alteration of OSC cultures by fibroblasts
(see Figure 6 and below), the OSC alone should be col-
lected from ovarian surface by sterile cotton swab moist-
ened in culture medium or using blunt edge of a sterile
scalpel. Culture processing, tissue culture media, hormo-
nal conditions, and other variables for primary OSC cul-
tures are available in Ref. [10].
Two to four OSC subcultures should be established.
To prepare in vitro approaches described below for the
early stage of OLC proper development, half of the
established OSC subcultures may be supported by a
small amount of mononuclear cells (including CD14
MDC and CD8 T cells), collected by their separation of
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fertile ABO blood typing compatible woman, perhaps
optimally during the beginning of the midfollicular
phase (one to four days after menstruation). An alterna-
tive would be to separate mononuclear cells from zero
blood typing transfusion bag collected at the same
follicular phase period.
If a donor zero blood group transfusion bag is utilized,
the remaining collected mononuclear cells can be proc-
essed for freezing and stored for utilization in additional
OSC cultures.
Donor mononuclear cells can ensure early stages of
emerging germ cell maturation, i.e., asymmetric division
of OSCs, chromosome crossover, and meiosis I symmet-
ric division - see Figure 1A-C and Ref. [24,26].
Formation of granulosa cells
In addition, granulosa cells also originate from OSCs by
the influence of DR+ MDC during the same follicular
phase period [26]. Interaction of OLCs with autologous
granulosa cells may ensure primary Balbiani body forma-
tion. For suitability of the culture for IVM, however, the
secondary Balbiani body should be formed, like in the
small antral follicles (see below). Therefore, self granu-
losa cells either associate with evolving OLCs, forming
primary follicle structures, or additional granulosa cells
should be added when some oocytes reach the 80-100
micrometers size and begin to form daughter cells to en-
rich their cytoplasmic organelles for further growth and
maturation.
Separation of donor mononuclear cells
The procedure of separating mononuclear cells [49]
would exclude the presence of lighter circulating donor
germ cells. Their presence in the blood from the early
midfollicular phase is, however, unlikely.
Collection of ovarian stem cells for a clinical approach
For clinical approaches, OSCs can be collected from in-
fertile women by laparoscopy, as previously reported
from the first clinical trial [26].
Use of ultrasound-guided and vacuum-assisted thicker
needle may be a simpler alternative for collecting loose
OSC from ovarian surface without patient’s bodily
anesthesia. This, however, may provide virtually pure
OSC, without other cellular components present in TA,
which also may be important. That may be fixed with
OSC culture support by a small amount of donor mono-
nuclear cells (see above).
Oocyte-like cell nuclear transfer to donor oocyte
The aforementioned nuclear transfer studies [45-48]
utilize enucleated donor metaphase-II (MII) oocytes with
normal mitochondrial composition. OLCs develop fromOSCs without any interaction with granulosa cells. This
procedure is associated with the absence of cytoplasmic
organelles required for later maturation. In contrast,
transfer of a nucleus (GV) from an OLC to an enucle-
ated donor GV oocyte, which is ready for IVM and still
contains cumulus granulosa cells, may represent a re-
constructed oocyte capable of IVM and IVF.Donor oocyte cytoplasmic transfer to oocyte-like cell
Heide Schatten and colleagues [8] in their contribution
to the IVF series dealt with a vital role of mitochondria
in oocyte functions. These authors suggested that MII
oocytes from women affected by metabolic disorders
may be improved by transfer of 10-15% mitochondria
from cells exhibiting mitochondrial integrity into
mitochondria-impaired oocytes.
As indicated above, the issue that may be solved by
transferring a nucleus from an OLC to an enucleated
donor GV oocyte which contains cumulus granulosa
cells is to provide proper novel cytoplasmic organelles
which otherwise would be lacking due to the absence of
granulosa cell-derived secondary Balbiani body. The
transfer of mitochondria and other organelles from
donor MII oocytes to OLCs may be an alternative to the
nuclear transfer suggested above.Transfer of granulosa cells or their components to an
established ovarian stem cell culture
Established OLC cultures usually contain OLCs of various
sizes which fail to express ZP proteins, contrasting the ZP
expression in oocytes developed in the presence of granu-
losa cells in ovarian follicles. As shown in Figure 6, larger
OLCs easily incorporate additional organelles for continu-
ation of their growth. Since they are unable to interact
with granulosa cells, they may either associate with fibro-
blasts that hybridize and kill the OLCs, or divide to pro-
duce daughter cells that support OLC growth although
not functional maturation.
Preferably, at the beginning several primary OLC cul-
tures (2 to 4) may be established from scrapped OSCs.
In order to induce the development of functional oo-
cytes from OLCs, addition of donor or non-donor
(where non-donor means allogeneic source free of
charge) granulosa cells, including collection of granulosa
cells after oophorectomy (except atretic follicles) in
women ≤35 years of age, would be recommended.
Granulosa cells from small antral follicles might be pref-
erable. To test the retrieved granulosa cells, they should
be added to a small part of the established primary cul-
tures to ascertain the formation of CK positive Balbiani
bodies within OLCs. If secondary Balbiani bodies were de-
tected by IHC in large OLCs, some other live subculture
may be subjected to IVM and IVF to develop embryos.
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secondary ovarian stem cell cultures during early steps of
oocyte reconstruction
Primary OSC cultures (see previous section for the es-
tablishment of multiple primary cultures) can be trypsi-
nized and stored frozen for later utilization. Figure 7
shows images from time lapse cinematography of oocyte
development in a secondary OSC culture, beginning 4 h
after seeding. Video excerpts are available as Additional
file 1: Video S1.
The behavior of OLCs in secondary culture shows a
new formation of the ooplasm with full volume from the
available culture medium and its components. It resem-
bles a situation of oocyte expansion between its capture
by granulosa cell nests (see Figure 4A) and early formation
of new primary follicle when primary Balbiani body is
formed (see Figure 4B). It is possible that if the fresh intact
live granulosa cells are added shortly after the secondary
culture is seeded, they may contribute to the Balbiani body
formation in the reconstructing OLCs during secondary
culture. Optimally, a few OLCs and few granulosa cells in
a small culture medium volume may be incubated to-
gether in a single well using, for instance, 96 well plates.
If unsuccessful to form the Balbiani body after adding
granulosa cells, the mixed OLC and granulosa cell cul-
ture may be subjected to trypsinization, and after freez-
ing for several days, left to develop as a new mixed
secondary culture.
The use of trypsinized granulosa cells without any
former culturing, or cocultured with OLCs freshly devel-
oped in secondary culture may be another possibility.
However, it should be noted that the longer lasting gran-
ulosa cell cultures exhibit a dense fibroepithelial cell01’:15” 1
F36
25 µm 
OLC gradual renewal in the secondary cult l l i  t   lt
BA
Figure 7 Time lapse video of oocyte reconstruction in secondary OSC
B) Multiple cytoplasmic eruptions (arrowheads). C) Development of the 50
arrowhead a polar body). Time in min':sec". Movie segments are available in thcharacter [27], possibly due to their reversal to fibroblast
type OSC precursors in the TA (see Figure 5A and B).
Such cells will not represent functional granulosa cells
suitable for the Balbiani body formation.
Finally, a crude (unfiltered) homogenate of uncultured
granulosa cells, either fresh or frozen, could be added to
the fresh secondary OLC culture. This will enable
renewing OLCs to include granulosa cell components
from the granulosa cell cytoplasm-enriched culture
medium.
Optimally, granulosa cells should be autologous, but it
would be unrealistic to obtain such cells in ovarian infer-
tility cases. Other available sources will be cumulus cells
from donors. The non-donor source may be cumulus
cells from IVM cases. In addition, granulosa cells re-
trieved after ovariectomy of fertile women ≤35 years of
age may be another option (see above).
One of the OLC subcultures should be tested by IHC
for the presence of CK positive Balbiani bodies in devel-
oping oocytes. In addition, expression of ZP3 at the oo-
cyte surface, which is absent during early follicular
development (Figure 8A vs. B) [41], may be included.
As indicated above, primary Balbiani body is formed
during follicular renewal, but disappears in resting pri-
mary follicles (see Figure 5I). The Balbiani body is also
absent in the growing preantral follicles (Figure 8C) but
a secondary Balbiani body is formed in small antral folli-
cles (Figure 8D). This is a stage when oocytes initiate the
expansive growth and become sensitive to gonadotro-
pins, since they are capable of meiosis II resumption and
may be used for IVM.
In culture, such larger OLCs need additional cytoplas-
mic organelles and they attempt to receive them from8’:07” 31’:14”
ure, suitable for functional refurbishing, it l  f  f ti l f i i
C
culture. A) Early developing cell with a cytoplasmic tail (arrowhead).
micron oocyte-like cell (yellow arrowheads indicate cell surface, red
e Additional file 1: Video S1. Reprinted from Ref. [26]: © Antonin Bukovsky.
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Figure 8 ZP and CK expression in ovarian follicles. A) Oocytes in resting primary follicles lack ZP3 expression, but express ZP1, ZP2, and ZP4
[41]. B) ZP3 is expressed in the oocyte of a growing preantral follicle. C) Double color IHC for CK (brown) and ZP (blue) expression in a growing
preantral follicle. CK is expressed in granulosa cells (GrC) but no secondary Balbiani body is present in the oocyte. Oocyte surface expresses ZP
(blue arrowhead). D) Double color IHC for CK (blue) and ZP (brown) expression in a small antral follicle. CK is expressed in granulosa cells (GrC)
and in the oocyte secondary Balbiani body (blue arrowhead). Oocyte surface expresses ZP (orange arrowhead).
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cells (see Figure 6D and E). Such additional organelles
are sufficient for advanced OLC growth [26], but they
are inappropriate for meiosis II resumption.
The presence of larger OLCs with a poor content of
optically dense cytoplasmic organelles (see open white
arrow, Figure 6A) may indicate that they originated from
germ cells already passing the chromosomal crossover,
meiosis I, and preantral follicular development stages.
Adding granulosa cells to such OLC culture could be
optimal for enabling OLCs to form secondary Balbiani
bodies. This may be followed by resumption of meiosis
II by IVM and successful IVF.
Fibroblasts in OSC cultures steal ZP3 expression from
OLCs
Zona pellucida glycoprotein 3 (ZP3) has been recently
shown to act as a primary sperm receptor for sperm-egg
binding in humans [50]. Figure 9 shows a weak nuclear
ZP3 expression, indicating a preparation for cytoplasmic
ZP3 synthesis, and no ZP3 expression in associated satellite
cell and fibroblasts in untreated OSC culture from a 50
year old human female (F50). The treatment of another
F50 culture with hCG caused marked nuclear and surface
ZP3 expression in OLC and regressing satellite cell. The
accompanying fibroblasts, however, steal the OLC and sat-
ellite cell organelles, including ZP3 protein. It is also shown
that in FSH & hCG treated OSC culture from POF women
in the former clinical trial (see Ref. [26]) the sperm curi-
ously associated with fibroblasts, but not with the OLCs.
This suggests that in gonadotropin treated OSC cultures
the fibroblasts but not OLCs express the ZP3 glycoprotein.These observations indicate that OLCs in OSC cultures
express LH receptor, which is in vivo derived from primary
Balbiani body formed by granulosa cells accompanying for-
mation of new primary follicles (see above). The follicular
basement membrane, which is absent in OSC cultures, pre-
vents association of ovarian fibroblasts to drain cytoplasmic
organelles from the developing oocyte.
The hCG causes ZP3 expression by OLCs but fibroblasts
present in OSC cultures cause functional deprivation of de-
veloping OLCs, either by direct association with OLCs , or
by association with OLC-satellite cell complexes. Because
of that, the presence of fibroblasts in OSC cultures should
be avoided.What may be next in ovarian tissue cultures?
Laboratory experiments and IVM testing should deter-
mine which component(s) of granulosa cells, e.g.
luteinizing hormone receptor (LHR) expression in cu-
mulus cells [51], is/are essential for the transition of the
immature GV to the MII stage, first polar body formation,
and fertilization. To express LHR, the granulosa cells
should be pre-treated with follicle stimulating hormone
[52]. The presence of essential component(s) in the
medium of primary or secondary OLC cultures may en-
hance maturation of the OLCs. However, such treatment
may not ensure the need of additional cytoplasmic organ-
elles, optimally provided by granulosa cells. Nevertheless,
the germ and granulosa cells originate from the same
OSCs. The presence of essential components in the
medium and collection of additional organelles from OLCs
daughter cells may be sufficient for the IVM approach.
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Figure 9 ZP3 expression by OLCs in IVM treated OSC cultures is stolen by fibroblasts. A) OLCs in untreated OSC cultures show week
nuclear ZP3 expression, which is absent in accompanying satellite cells (SC) and fibroblasts (FB). Arrowheads indicate tube like ring canals
between OLC and SC. Arrows indicate bindings of FBs to the OLC. B) After hCG treatment the OLC exhibits strong nuclear and surface (black
arrowhead) ZP3 expression, which is also present in accompanying SC (white arrowhead). The ZP3 expression is stolen by FBs (red arrowheads),
leaving the surface of OLC ZP3 depleted (open arrowhead). C) The OSC culture from a 30 years old POF female was IVM (FSH+hCG) pretreated
and fertilized with the husband's sperm. The phase contrast (PhC) image from a live culture shows that virtually all sperm are associated with
fibroblasts instead with OLCs.
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infertility treatment
In 2005 Conboy and colleagues studied shared circula-
tory system between old and young mice (heterochronic
parabiosis) and concluded that age-related decline of
progenitor cell activity in aged mice can be improved by
young mouse serum [53]. More recently H. L. Katcher
analyzed studies attempting to restore young function of
tissues in aging animals and concluded that “It appears
that the plasma of young animals is sufficient to cause
cellular rejuvenation of old stem cell populations” [54].
The circulating TGF-beta superfamily member growth
differentiation factor 11 (GDF11) declines in aged mice,
and treatment with GDF11 reversed age-related cardiac
hypertrophy [55]. Factors found in young blood induce vas-
cular remodeling, culminating in increased neurogenesis
and improved olfactory discrimination in aging mice [56].
A possibility of heart or brain rejuvenation in older human
individuals by plasma content in blood transfusion from
young individuals [55-62] had currently received significant
press attention [63-66].
The aging of some tissues is, however, more complex,
then the effect of blood plasma soluble contents decline.
The circulating mononuclear cells home in tissues, to
which they have been committed during early ontogeny,
and longevity of such commitment depends on the tis-
sue appearance during early ontogeny [43]. The tissues
beginning their function very early (during embryonic
period, when the immune system is not yet in more
advanced development), like the heart, can function for
hundred years in humans. The ovary, which primary fol-
licles first differentiate with the assistance of immune
system-related cells at six month of intrauterine life, is
fully functional till about 38 ± 2 years of age, when the
immune functions begin to decline [16].Immune system related cells cause asymmetric division
and differentiation of epithelial [36] and other tissue types
[67], including the ovary [34]. The extent of differentiation
of distinct tissues is different. Squamous epithelia differen-
tiate completely, up to the apoptosis of superficial cells
with the help of immune system components (monocytes,
T cells, dendritic cells, and immunoglobulins [36]), and
skin is significancy altered in aging individuals due to the
diminished epidermal barrier repair associated with a de-
pletion of naive T cells [68]. However, maintenance and re-
pair of some other tissues (skeletal and hart muscles,
brain) in young individuals should be prevented from an
involvement of the T cells [17]. For repair these tissues in
aging individuals, the transfer of blood plasma from young
donors containing GDF11 can be sufficient.
Taking together, the heterochronic parabiosis causing tis-
sue improvement in aged mice [53] is not caused by serum
soluble factors only, but also, at least in some instances, by
circulating mononuclear cells from young individuals. This
applies to mammalian female reproductive tissues, includ-
ing humans, in particular (reviewed in Ref. [34]).
A question arises whether compatible small blood vol-
ume replacement (or mononuclear cell transfer without
or with blood plasma) from a young healthy fertile and
ethnically relevant woman donor, perhaps 300–500 ml,
optimally collected during the beginning of the midfolli-
cular phase (one to four days after menstruation), and
transfused to infertile women may be sufficient for treat-
ing women with ovarian infertility, which still carry ovar-
ian stem cells. If whole blood transfusion is chosen, it
should be performed as a small blood volume replacement
in order to prevent erythrocyte overdose, i.e. immediately
after the corresponding blood volume withdrawal.
Accordingly, small blood volume replacement or
mononuclear cell transfer from a young healthy fertile
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infertility.
Systemic treatment of ovarian infertility by a small blood
volume replacement or separated mononuclear cells from
young healthy fertile donor women
Circulating immune system related mononuclear cells
(MDC and T cells) regulate function of virtually all tis-
sues in the body (reviewed in Ref. [17,36]).
Transfer of mononuclear cells by a small blood volume
replacement form young fertile women may cause tempor-
ary rejuvenation of the immune, ovarian, and endocrine
systems. The plasma content of immune components in
the blood, e.g., antibodies, may eliminate eventual persist-
ing follicles that enclose aged oocytes unsuitable for IVF.
In contrast, mononuclear cell content may cause follicular
renewal consisting of fresh autologous oocytes and granu-
losa cells.
Although certain limitation for such approach may be
the presence of circulating donor germ cells after blood
transfer, such cells are not expected to be present dur-
ing the beginning of midfollicular phase, and even if
present, they would not find available uncommitted
granulosa cell nests for their transformation into oo-
cytes in primary follicles, and would quickly degenerate
(see Figure 4D and E).
Eventually, the donor lighter circulating germ cells
may be excluded by the vascular transfer of smaller and
heavier mononuclear white blood cells separated from
the whole blood. Transfer of mononuclear cells alone,
however, would also exclude plasma components present
in the blood, including hormonal conditions and plasma
proteins during the early midfollicular phase, which also
may be important.
To deal with this, transfusion of separated mono-
nuclear cells and blood plasma will be most desirable,
since this will include soluble blood proteins and hor-
mone components and exclude unnecessary erythro-
cytes. In particular, the inclusion of plasma components
might be desirable in POF and polycystic ovary syn-
drome infertile women, and in women lacking the men-
strual cycle. Transfer of mononuclear cells (without or
with plasma) will not require, due to the lack of erythro-
cytes, a withdrawal of the of patient’s small blood
volume.
Consequently, there are three options to consider:
A) Simple small blood volume replacement
B) Transfusion of separated mononuclear cells
C) Transfusion of separated mononuclear cells and
blood plasmaIn cycling infertile women, blood or mononuclear cell
transfusion should be optimally performed during theearly midfollicular phase. The first new primary ovarian
follicles, formed by new oocytes and granulosa cell
nests, may occur after a period of two to three months
(see Figure 5 comments above). Their growth into
antral follicles suitable for ovarian stimulation prior to
IVF may require about two to three additional months.
Differentiation of preantral and small antral follicles
would require a lasting influence of the spectrum of hor-
monal and growth factors effects [69], which may be-
come temporarily available in the rejuvenated ovary and
endocrine system after mononuclear cell transfer. Opti-
mally, the treatment will cause elimination of old aged
follicles with dysfunctional oocytes, resulting in a tem-
porary disappearance of the menstrual cycle before the
fresh new follicles reach functional maturity. Follicular
renewal may last for several months after the rejuvenat-
ing treatment. The new follicle cohorts (restored
ovarian reserve) and restored ovarian function may last
for several years. The experience will show.
The differentiation of some new follicles within ovar-
ies, accompanied by hormonal stimulation for their dif-
ferentiation into at least small antral follicles may also
be considered. This would be sufficient for utilization of
oocytes in IVM and fertilization procedures giving preg-
nancy rates between 22% to 55.6% [70]. Sequential dif-
ferentiation of the remaining follicles in the new
cohort(s) may also be expected.
If needed, additional small blood volume replacement
or separated mononuclear-cell transfusion from a differ-
ent young healthy fertile woman donor may be consid-
ered after a 6 month period.
Systemic treatment of testicular infertility by small blood
volume replacement from young healthy fertile donor men
It is important to note again that even with suitable
fresh oocytes developed in older women, the sperm of
some older men may cause fetal genetic abnormalities
[21]. In addition, infertility of human males affects al-
most a half of infertility cases worldwide [71]. It has
been shown that depletion of MDC in one testis of adult
rats selectively abolished differentiation of Leydig cells
from mesenchymal precursors [72]. Recent findings indi-
cate that CD14 MDC in circulation are involved in a
variety of physiological functions other than innate and
acquired immune responses, such as repair and regener-
ation of tissues [73]. It might be possible that small com-
patible blood volume replacement from young fertile
and currently sexually active men may improve the tes-
ticular fertility and sperm quality in older or infertile
men, and in azoospermia. The same may apply for prob-
lematic intracytoplasmic sperm injection cases. This may
apply to older couples, where women are treated for
ovarian infertility, in particular. The expected temporary
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prior conception or fertilization, when the new sperm
can be expected to be available [74]. After initiation of
the treatment, occasional masturbation is recommended
to deplete the old sperm.
Systemic treatment of other functional diseases by tissue
rejuvenation
Utilization of small blood volume replacement from young
healthy individuals
As indicated above, there is a recent boom dealing with
the blood plasma involvement in rejuvenation of aging
tissues [53-66]. Here we propose for the first time that
blood mononuclear cells are essential for rejuvenation of
those tissues, where immune system components par-
ticipate in an appropriate division and differentiation of
tissue stem cells.
The body rejuvenation by functional mononuclear
cells and blood plasma from young healthy individuals
of the same sex and ethnicity could represent a practical
clinical approach causing a decline of in vitro method-
ology in favor of in vivo treatment. If needed, functional
mononuclear cells from distinct young healthy individ-
uals could be utilized in six month intervals.
For in vivo approach it will be important to use small
volume blood replacement instead of simple blood
transfusion. The blood replacement can be omitted
when mononuclear cells, optimally along with the
plasma, are used.
Alternatively, such mononuclear cells should accom-
pany in vitro methodology and its in vivo application.
Systemic use of young mononuclear cells from young
donor should be applied shortly before the in vitro
methodology is applied in vivo.
Systemic and local use of honey bee propolis
Improvement of homeostatic functions of the immune
system related cells can also be induced by honey bee
propolis in animal and in vitro models of functional dis-
eases [75-77]. Animal and cell culture experiments indi-
cate that the propolis utilization strengthens the body’s
immune system and activates the thymus [78-81]. The
immune system itself, including its homeostatic func-
tions [17,67], is significantly deteriorating with the age
advancement. Thymic involution associated with age ad-
vancement is delayed in human females compared to
males [82]. This might be why males are earlier affected
by aging compared to females, and why the women live
longer due to the better preservation of a role of the im-
mune system in body homeostasis.
Improvement of hypertension and type 2 diabetes,
allowing 50% decrease of medications, was observed
after oral systemic use of propolis ethanol extract (prop-
olis tincture). Local propolis application totallyprevented formation of dental calculus, break off alopecia
progression, improved aged skin conditions, and caused
regression of varicose veins (unpublished observations).
Animal experiments indicated that propolis diet resulted
in significant decrease of systolic blood pressure in spon-
taneously hypertensive rats, but had no effect on normal
rat controls [75]. Propolis ethanol extract was reported
to attenuate blood glucose and plasma cholesterol in
ob/ob mice [76]. Ethanolic soluble derivative of prop-
olis extract administered to diabetic mouse models
increased the number of immunoregulatory T cells,
causing decrease of blood sugar levels [83]. Propolis
administered to rats by oral gavage reduced blood glu-
cose levels in diabetes and might be beneficial for the
treatment of periodontitis [84]. Propolis flavinoids
liposome could effectively activate the cellular and
humoral reactivity of immune cells in mice, including
proliferation rates of splenic lymphocytes [77].
A question arises, whether propolis can improve ovar-
ian and testicular function. Isolated recent report sug-
gests that toxic effects of methoxychlor on rat ovaries
were neutralized by the administration of propolis [85].
Available animal and human studies indicate that propolis
have a protective effect and stimulates sperm function
[86-91]. The question whether propolis can improve ovar-
ian or testicular age-induced infertility has not been stud-
ied yet.
Conclusions
From the Darwinian point and nature view, it is un-
acceptable that adult higher vertebrate females are over-
whelmingly referred to carry primordial follicles
persisting from the fetal period of life, with 15-35 years
old “functional” oocytes in human females.
Apparently, human oocytes begin to age after 35-40
years of women’s age, when the number of oocytes and
primary follicles begins to significantly decline [12,13].
This is due to the follicular renewal cease, which is
caused by the lack of available uncommitted granulosa
cell nests [33,34]. Formation of new granulosa cells is
immune system dependent (see above). Therefore, a
lack of formation of granulosa cells is a consequence of
the age-induced alterations of homeostatic immune sys-
tem functions [17] beginning in humans from the age of
35 years [16]. At the same age, the ovarian infertility be-
gins to sharply increase [7].
The data presented show that like in the plants, inver-
tebrates, lower vertebrate females, and higher vertebrate
males, the formation of new germ cells and gametes per-
sists in women during the prime reproductive period in
adulthood.
In adult fertile human females, the new germ cells are
derived by asymmetric division from CK+ OSCs, exhibit
depletion of CK and MHC-I expression, show meiosis I
Bukovsky Reproductive Biology and Endocrinology  (2015) 13:10 Page 18 of 21events, and contribute to the cyclic follicular renewal.
Bipotential CK+ OSCs are also a source of new granu-
losa cells required for the follicular renewal. The follicu-
lar renewal is also dependent on support of circulating
blood mononuclear cells. They induce intermediary
stages of meiosis (metaphase I chromosomal duplication
and crossover, telophase, and cytokinesis) in emerging
ovarian germ cells, as for the first time demonstrated
here. They also induce formation of granulosa cells, and
stimulate follicular growth and development. These
functions of CK+ OSCs and blood mononuclear cells
are already present in midpregnancy fetal ovaries. The
only role of primordial germ cells is to imprint the CK+
OSCs (and stem cells in some other tissues - e.g. skin)
toward a potential differentiation into fetal and adult
germ cells. Similarly to embryonic stem cells, the OSCs
are also capable to differentiate into other cell types,
depending on the local in vivo or in vitro conditions.
Based on these measures, the current nomenclature
should be revised as follows: Fetal and Adult ovarian
germ cells, New primary follicles, and Resting
primary follicles.
The high demand by older women to conceive and
give birth to their own children together with the in-
creased infertility after the age of 40 years raises a prob-
lem to be solved by IVF/IVM approaches. The same
applies for younger women with POF, or other younger
women with ovarian infertility.
In vitro development of OSC-derived OLCs is inde-
pendent of the woman’s reproductive aging. The clinical
utilization of OLCs in POF women is, however, still un-
successful. Among the proposed strategies to solve this
matter and enable pregnancy in women with ovarian in-
fertility, nuclear transfer to a donor oocyte or cytoplas-
mic transfer from a donor oocyte raise ethical and social
concerns in some countries in terms of three parent
pregnancy [92], but it can be used in other countries. In
addition, these techniques should be worldwide tolerable
in women considering to become pregnant from oocyte/
embryo donation, which is an accepted event of the
three parent pregnancy.
Utilization of intact granulosa cells and/or their puri-
fied components in OLC cultures may be essential. A
better understanding of granulosa cell component(s) is
needed (e.g. LHR) for oocyte maturation from the mei-
osis I to meiosis II stage. Passage it/them to the medium
of the fresh secondary OLC culture in a purified form,
may be followed by successful IVM and IVF. Additional
observations presented for the first time here also indi-
cate that presence of fibroblasts in OSC cultures should
be avoided, since they steal cytoplasmic organelles, in-
cluding ZP3 glycoprotein needed for the sperm-egg
binding, from the developing and hCG stimulated
OLCs.Ovarian infertility may possibly be treated also without
OLC cultures, by compatible small blood volume re-
placement or transfer of mononuclear cells separated
from the blood of a young healthy fertile woman donor,
and eventually accompanied by the blood plasma. This
may renew the “steps required for follicular renewal in
adult human ovaries” and renew the ovarian reserve, which
may function for several additional years (see above).
If the formation of new primary follicles and their dif-
ferentiation in adult human ovaries of women with ovar-
ian infertility took place after compatible small blood
volume replacement or transfer of mononuclear cells
(without or with blood plasma) from young healthy
fertile women, it would represent a practical clinical
approach causing a decline of in vitro methodology in
favor of in vivo treatment, as proposed by Deepa
Bhartiya and colleagues [9] in the IVF article series [1].
It is proposed that the simple and inexpensive in vivo re-
sumption of follicular renewal should be attempted in
women with ovarian infertility as the first step - for women
considering pregnancy from oocyte/embryo donation, in par-
ticular. Although unlikely, it would be important to deter-
mine whether donor mononuclear cells can cause a three
parent baby. If so, each blood transfusion woman recipient,
and possibly also man, should be made aware of that.
Infertile patients attending IVF centers may request a
suitable relative or friend with matching ABO blood and
Rh factor typing for proper ovarian cycle period blood
collection and small blood volume replacement at a
transfusion unit. Optimally, a purchase of compatible
blood or separated mononuclear cells (without or with
blood plasma) collected from young healthy fertile
women during early midfollicular phase from transfusion
units may be negotiated by IVF centers, and small
blood volume replacement or mononuclear cell trans-
fer performed at the similar ovarian cycle period in
cycling infertile patients. Interestingly, a successful
pregnancy has been reported after allogeneic bone mar-
row transplantation in a patient with chronic myeloid
leukemia [93].
Some of the novel proposed in vitro approaches (see
above) may be used as a second option, which can pro-
vide much faster (within four to six weeks) treatment of
ovarian infertility. These approaches may generate oo-
cytes suitable for IVM/IVF outside of the more complex
in vivo body conditions, such as formation of human
granulosa cell nests, their transfer from the ovarian sur-
face to the lower ovarian cortex, vascular transport of
germ cells, and formation of new primary follicles by as-
sociation of developing small oocytes with intravascular
granulosa cell nests [23,24,26,34,35]. Some of these pro-
cesses may in vivo be under autonomic innervation con-
trol [17,34,94], which may not be possible to restore by
mononuclear cell transfer alone.
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adult mammalian ovaries [95] are now for the first time
demonstrated here in humans, evidencing that the germ
cell and follicular renewal exists during the prime repro-
ductive period. Follicular renewal is dependent on the
support of OSC-committed circulating blood mono-
nuclear cells, which are required for renewal of functional
germ and granulosa cells from OSCs. The granulosa
cell-committed mononuclear cells can be depleted in
older women. They may also be absent in other cases of
ovarian infertility, along with, or without the absence of
mononuclear cells committed for renewal of adult germ
cells.
A combination of blood or separated mononuclear
cells transfusion with laparoscopic (or ultrasound-guided
and vacuum-assisted) collection of OSCs for in vitro cul-
tures several days thereafter, is a third possibility. This
may allow a collection of autologous new ovarian germ
cells passing the crossover and meiosis I division in the
ovarian TA, and freshly developed granulosa cells for
in vitro processing.
The compatible small blood volume replacement from
young fertile and currently sexually active men may also
be a suitable and easy approach for the treatment of tes-
ticular infertility and sperm quality improvement in
older or other affected men, in azoospermia, and for
problematic intracytoplasmic sperm injection cases. This
will apply to older couples, where the women are treated
for ovarian infertility, in particular. The testicular reju-
venation should be initiated three months prior concep-
tion or in vivo/in vitro fertilization.
The body rejuvenation by a compatible small blood
volume replacement from young healthy individuals of
the same sex and ethnicity could represent a practical
clinical approach for human functional diseases, causing
a decline of in vitro methodology in favor of in vivo
treatment. If needed, compatible small blood volume
replacement or mononuclear cell transfer from distinct
young healthy individuals could be utilized in six month
intervals for repair of young altered or aged reproductive
and other tissue functions. Alternatively, such mono-
nuclear cells could accompany in vitro methodology
and its in vivo application.
Systemic and local use of honey bee propolis, strength-
ening the homeostatic immune function in aging indi-
viduals, is another option for rejuvenation of tissues in
older individuals. The role of propolis in the treatment
of age-associated ovarian and testicular infertility has
not been, however, comprehensively studied yet.
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